We studied the effect of pH (7.1, 6.3, and 5.8) on the in vitro susceptibilities of 59 isolates of Bacteroides fragilis and 60 isolates of other B. fragilis group species to trovafloxacin, ciprofloxacin, clindamycin, ampicillinsulbactam, piperacillin-tazobactam, imipenem, and meropenem. For each agent tested the geometric mean MIC was highest at pH 5.8, intermediate at pH 6.3, and lowest at pH 7.1. The magnitude of the pH effect varied greatly among different antibiotics. These data show that an acidic pH decreases the in vitro susceptibilities of the B. fragilis group to several antibiotics.
Acidic pH conditions are the rule in mixed aerobic-anaerobic infections when abscess formation occurs (1) . However, the in vitro susceptibilities of bacteria to antimicrobial agents are traditionally tested in media with a neutral pH. The role of an acidic pH and low oxygen tension in decreasing the in vitro susceptibilities of several bacterial species to aminoglycosides has been demonstrated (1, 4) . This phenomenon has been implicated as a factor in the reduced efficacy of aminoglycosides in the treatment of intra-abdominal infections (16) . An acid environment influences the antimicrobial activities of antibiotics of several classes including beta-lactams and fluoroquinolones (5-7, 9, 11, 12) . Therefore, the local pH in infected tissue may be one factor affecting the choice of antibiotics in the treatment of mixed infections (1, 10, 23) .
The Bacteroides fragilis group is the major anaerobic pathogen involved in the pathogenesis of intra-abdominal abscesses. Previous studies suggested that the in vitro susceptibilities of the B. fragilis group to ciprofloxacin, ceftizoxime, and imipenem are decreased in acidic conditions (2, 3, 15) . We further explored the effect of pH on the in vitro susceptibilities of the B. fragilis group to selected antimicrobials, including newer agents with antianaerobic activity such as trovafloxacin and meropenem.
Organisms were randomly obtained from a collection of B. fragilis group clinical isolates (isolated in 1994) from eight medical centers participating in an ongoing in vitro susceptibility survey of the B. fragilis group (19, 20) . Identification of all organisms was confirmed by standard methods. The antimicrobials were prepared at 10 times the desired concentration and kept frozen at Ϫ70°C until the day of use.
In vitro susceptibility was determined by a broth microdilution procedure of the National Committee for Clinical Laboratory Standards (NCCLS) (13). A 0.1 M citrate-phosphate buffer, adjusted to a pH of 7.1, 6.3, or 5.8 was incorporated into the test medium. The pH of the broth was checked before autoclaving, after autoclaving, and after the addition of each antimicrobial agent. Broth microdilution trays were prepared and kept frozen at Ϫ70°C until the day of use. On the day of testing, organisms were grown to log phase in brain heart infusion broth. The cultures were then diluted into prereduced Wilkins-Chalgren broth of the pH to be tested to deliver a final inoculum of approximately 10 5 CFU/well in the test plates. Plates were incubated in an anaerobic chamber at 37°C and read at 48 h. The MIC was defined as the lowest concentration that inhibited visible growth. Breakpoints to define fully resistant strains were based on recent NCCLS guidelines (13). Strains with intermediate susceptibility test results were included in the susceptible category. For trovafloxacin and ciprofloxacin, tentative breakpoints used were 4 g/ml. The geometric mean MICs of the antibiotics against all isolates of the B. fragilis group tested at three different pHs are given in Fig. 1 . The geometric mean MIC at pH 5.8 was higher than the geometric mean MIC at pH 6.3, which was higher than the geometric mean MIC at pH 7.1, for all agents tested. The magnitude of the pH effect varied among different antibiotics. The relative geometric mean MICs at pH 5.8 and 6.3 compared to the geometric mean MIC at pH 7.1 were, respectively, 3 Table 1 shows the MICs at which 50% of the isolates are inhibited (MIC 50 s), MIC 90 s, and percentages of resistant strains at breakpoint for the seven antibiotics tested at pH 7.1, 6.3, and 5.8 against B. fragilis and other B. fragilis group species.
The percentages of strains resistant to clindamycin, ampicillin-sulbactam, and piperacillin-tazobactam were not affected by the acidic pH (Table 1) . With respect to the two carbapenems tested, the MIC of imipenem was Ͼ16 g/ml for 81% of the strains while the MIC of meropenem was Ͼ16 g/ml for only 1% of the strains at pH 5.8 (P ϭ 0.001). With respect to the two quinolones tested, the MIC of ciprofloxacin was Ͼ4 g/ml for 98% of the strains while the MIC of trovafloxacin was Ͼ4 g/ml for 18% of the strains at pH 5.8 (P ϭ 0.001). The MICs of trovafloxacin against B. fragilis strains were less likely than those against strains from other B. fragilis group species to be Ͼ4 g/ml at pH 5.8 (5 versus 30% [ Table 1 ]).
Our data show that the in vitro susceptibilities of the B. fragilis group to all seven antibiotics tested are decreased at an acidic pH. A more profound effect was observed at pH 5.8 compared to pH 6.3. However, there is a considerable variance in the magnitude of the pH effect for the different antimicrobials. With respect to the two carbapenems tested, the MIC of imipenem increased considerably at an acidic pH, while the MIC of meropenem was only slightly affected. Our results are in accord with those of a preliminary report (14) and a study of only eight isolates (24) in which a significant decrease of the in vitro activity of imipenem against B. fragilis at an acidic pH was demonstrated.
The effect of pH on the in vitro and in vivo susceptibilities of bacteria including the B. fragilis group to antibiotics may be mediated through several mechanisms. First, pH influences the permeability of bacteria to antibiotics, as shown in studies of permeability to beta-lactams in B. fragilis (8) . Second, the stability and activity of enzymes which inactivate antibiotics are affected by pH, as shown in studies of ␤-lactamase activity of B.
fragilis (14) . Finally, the stability and kinetics of certain antibiotics are influenced by pH (1, 17, 22) .
Although it seems evident from our data that acidic pH affects the in vitro susceptibilities of the B. fragilis group to several antibiotics, the clinical significance of this phenomenon is unclear. For example, the in vitro activity of imipenem against the B. fragilis group is significantly decreased at an acidic pH, yet this agent is among the agents of choice in the treatment of intra-abdominal infections (21) .
The clinical utility of the in vitro antimicrobial susceptibility testing of anaerobic bacteria has not been studied extensively. However, recent data suggest that there is a correlation between in vitro susceptibility and outcome for infections caused by B. fragilis (18) . Therefore, this paradox of decreased activity at an acidic pH and generally good clinical outcome is unresolved.
In summary, acidic pH decreases the in vitro susceptibilities of the B. fragilis group to several antimicrobial agents. Future studies should explore the clinical relevance of these laboratory results and the utility of the in vitro antimicrobial susceptibility testing of anaerobic bacteria for patients with infections due to anaerobes. We thank June Cox-St. Pierre and Barbara Rapino for technical assistance and Roselia Martinez for secretarial assistance.
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